{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:36:28Z","timestamp":1780508188597,"version":"3.54.1"},"reference-count":28,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008070","name":"Department of Medicine, University of California, San Francisco","doi-asserted-by":"publisher","award":["Academic Senate Committee on Research"],"award-info":[{"award-number":["Academic Senate Committee on Research"]}],"id":[{"id":"10.13039\/100008070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008070","name":"Department of Medicine, University of California, San Francisco","doi-asserted-by":"publisher","award":["Pathways to Discovery"],"award-info":[{"award-number":["Pathways to Discovery"]}],"id":[{"id":"10.13039\/100008070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007117","name":"Peter Michael Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007117","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["Young Investigator Award"],"award-info":[{"award-number":["Young Investigator Award"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","award":["Harry F. Bisel, MD Endowed Young Investigator Awar"],"award-info":[{"award-number":["Harry F. Bisel, MD Endowed Young Investigator Awar"]}],"id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["CA177555"],"award-info":[{"award-number":["CA177555"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["K08 Al139375"],"award-info":[{"award-number":["K08 Al139375"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA223484"],"award-info":[{"award-number":["R01CA223484"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["U01CA233100"],"award-info":[{"award-number":["U01CA233100"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009779","name":"Bladder Cancer Advocacy Network","doi-asserted-by":"publisher","award":["Discoveries Young Investigator Award"],"award-info":[{"award-number":["Discoveries Young Investigator Award"]}],"id":[{"id":"10.13039\/100009779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006747","name":"San Francisco State University","doi-asserted-by":"publisher","award":["Development of Research and Creativity Grant"],"award-info":[{"award-number":["Development of Research and Creativity Grant"]}],"id":[{"id":"10.13039\/100006747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006747","name":"San Francisco State University","doi-asserted-by":"publisher","award":["Presidential Award"],"award-info":[{"award-number":["Presidential Award"]}],"id":[{"id":"10.13039\/100006747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,3,21]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>CTLA-4 blockade with ipilimumab is Food and Drug Administration-approved for melanoma as a monotherapy and has been shown to modulate the circulating T-cell repertoire. We have previously reported clinical trials combining CTLA-4 blockade with granulocyte-macrophage colony-stimulating factor (GM-CSF) in metastatic melanoma patients and in metastatic castration resistant prostate cancer (mCRPC) patients. Here, we investigate the effect that cancer type has on circulating T cells in metastatic melanoma and mCRPC patients, treated with ipilimumab and GM-CSF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used next-generation sequencing of T-cell receptors (TCR) to compare the circulating T cells of melanoma and mCRPC patients receiving the same treatment with ipilimumab and GM-CSF by Wilcoxon rank sum test. Flow cytometry was utilized to investigate specific T-cell populations. TCR sequencing results were correlated with each T-cell subpopulation by Spearman\u2019s rank correlation coefficient. Of note, 14 metastatic melanoma patients had samples available for TCR sequencing and 21 had samples available for flow cytometry analysis; 37 mCRPC patients had samples available for sequencing of whom 22 have TCR data available at both timepoints; 20 of these patients had samples available for flow cytometry analysis and 16 had data available at both timepoints.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>While melanoma and mCRPC patients had similar pretreatment circulating T-cell counts, treatment induces greater expansion of circulating T cells in melanoma patients. Metastatic melanoma patients have a higher proportion of clones that increased more than fourfold after the treatment compared with mCRPC patients (18.9% vs 11.0%, p=0.017). Additionally, melanoma patients compared with mCRPC patients had a higher ratio of convergent frequency (1.22 vs 0.60, p=0.012). Decreases in clonality induced by treatment are associated with baseline CD8+ T-cell counts in both patient groups, but are more pronounced in the melanoma patients (r=\u22120.81, p&lt;0.001\u2009vs r=\u22120.59, p=0.02).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration numbers<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00064129\">NCT00064129<\/jats:ext-link>; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01363206\">NCT01363206<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2019-000368","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T08:15:19Z","timestamp":1588752919000},"page":"e000368","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct00064129","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01363206","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4748-3930","authenticated-orcid":false,"given":"Jason","family":"Cham","sequence":"first","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Kwek","sequence":"additional","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Paciorek","sequence":"additional","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"He","sequence":"additional","affiliation":[{"name":"San Francisco State University, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Fong","sequence":"additional","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y","family":"Oh","sequence":"additional","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Fong","sequence":"additional","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"2025100305452113000_8.1.e000368.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2025100305452113000_8.1.e000368.2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1595"},{"key":"2025100305452113000_8.1.e000368.3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cr.7310017"},{"key":"2025100305452113000_8.1.e000368.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3258"},{"key":"2025100305452113000_8.1.e000368.5","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1101204","article-title":"GM-CSF and ipilimumab therapy in metastatic melanoma: clinical outcomes and immunologic responses","volume":"5","author":"Kwek","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025100305452113000_8.1.e000368.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.13943"},{"key":"2025100305452113000_8.1.e000368.7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0240"},{"key":"2025100305452113000_8.1.e000368.8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.uct.2007.09.001","article-title":"Anti-CTLA4 antibody clinical trials in melanoma","volume":"2","author":"Ribas","year":"2007","journal-title":"Update Cancer Ther"},{"key":"2025100305452113000_8.1.e000368.9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/fon.14.196","article-title":"Ipilimumab in the treatment of prostate cancer","volume":"11","author":"Reese","year":"2015","journal-title":"Future Oncol"},{"key":"2025100305452113000_8.1.e000368.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.1584"},{"key":"2025100305452113000_8.1.e000368.11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/jid.2014.467","article-title":"Unfolding the mutational landscape of human melanoma","volume":"135","author":"Davar","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2025100305452113000_8.1.e000368.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.06.024"},{"key":"2025100305452113000_8.1.e000368.13","doi-asserted-by":"publisher","DOI":"10.1038\/nature11125"},{"key":"2025100305452113000_8.1.e000368.14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83465"},{"key":"2025100305452113000_8.1.e000368.15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3529"},{"key":"2025100305452113000_8.1.e000368.16","first-page":"4099","article-title":"Comprehensive assessment of T-cell receptor \u03b2-chain diversity in \u03b1\u03b2 T cells","volume":"114","author":"Robins","year":"2009","journal-title":"Immunobiology"},{"key":"2025100305452113000_8.1.e000368.17","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200323961"},{"key":"2025100305452113000_8.1.e000368.18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008211"},{"key":"2025100305452113000_8.1.e000368.19","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0227"},{"key":"2025100305452113000_8.1.e000368.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3461"},{"key":"2025100305452113000_8.1.e000368.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"2025100305452113000_8.1.e000368.22","doi-asserted-by":"crossref","DOI":"10.1186\/s12859-017-1544-9","article-title":"3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data","volume":"18","author":"Zhang","year":"2017","journal-title":"BMC Bioinformatics"},{"key":"2025100305452113000_8.1.e000368.23","first-page":"379","article-title":"A mathematical theory of communication","volume":"1948","author":"Shannon","year":"1928","journal-title":"Bell Syst Tech J"},{"key":"2025100305452113000_8.1.e000368.24","doi-asserted-by":"publisher","DOI":"10.2307\/1934352"},{"key":"2025100305452113000_8.1.e000368.25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.18637\/jss.v028.i05","article-title":"Building predictive models in R using the CARET package","volume":"28","author":"Kuhn","year":"2008","journal-title":"J Stat Softw"},{"key":"2025100305452113000_8.1.e000368.26","doi-asserted-by":"crossref","DOI":"10.1038\/srep13664","article-title":"Characteristics of tumor infiltrating lymphocyte and circulating lymphocyte repertoires in pancreatic cancer by the sequencing of T cell receptors","volume":"5","author":"Bai","year":"2015","journal-title":"Sci Rep"},{"key":"2025100305452113000_8.1.e000368.27","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1219010","article-title":"High-throughput T cell receptor sequencing reveals distinct repertoires between tumor and adjacent non-tumor tissues in HBV-associated HCC","volume":"5","author":"Chen","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025100305452113000_8.1.e000368.28","doi-asserted-by":"publisher","DOI":"10.1038\/nature22383"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2019-000368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:45:29Z","timestamp":1759495529000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2019-000368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,5,5]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/jitc-2019-000368"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2019-000368","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}